EU grants marketing authorisation to Sanofi’s VaxRabeo rabies vaccine for all ages

The European Commission approved Sanofi’s next‑generation rabies vaccine, VaxRabeo, for pre‑exposure and post‑exposure prophylaxis across all age groups. The decision follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use issued on 17 September 2026. Sanofi said the product uses Vero‑cell technology, offers a longer shelf life and improved heat stability, and demonstrated comparable immunogenicity and safety to the company’s existing rabies vaccines in clinical studies.

The approval adds a new option to the EU market, potentially expanding Sanofi’s vaccine sales in Europe and neighbouring EEA countries. The company expects the longer shelf life and better thermostability to facilitate distribution and uptake, especially in travel‑related vaccination programs.

  • 1The European Commission issued the marketing authorisation on 19 November 2026 for VaxRabeo (inactivated rabies virus, Wistar strain).
  • 2The EMA’s Committee for Medicinal Products for Human Use gave a positive opinion on 17 September 2026.
  • 3VaxRabeo is manufactured with Vero‑cell technology and is intended for both pre‑exposure and post‑exposure prophylaxis.
  • 4Clinical studies showed protective antibody levels comparable to Sanofi’s existing vaccines (Verorab and Imovax Rabies) in both adult and paediatric participants.
  • 5The vaccine’s formulation is designed to lower the risk of allergic reactions.
  • 6Sanofi states the product remains effective for five years and can be stored at up to 27 °C for 96 hours before reconstitution.

Sources